Study Finds No Link Between Alcohol Consumption, Risk of Parkinson Disease
Although men with moderate lifetime alcohol consumption were at higher risk of developing Parkinson disease (PD) compared with light drinkers, no significant link was found between alcohol consumption and risk of PD, according to study findings.
Although men with moderate lifetime alcohol consumption were at a higher risk of developing
Because the complex etiology of PD involves a myriad of genetic and environmental factors, the specific mechanisms of certain associations, such as cigarette smoking and caffeine intake with decreased risk of PD, remain poorly understood. In prior meta-analyses, alcohol consumption, which serves as another possible factor in the development of PD, was suggested to have an inverse association.
“The results, however, are as yet inconclusive: the inverse association was mainly observed in retrospective case-control studies, but was not as clear in studies based on prospective cohorts,” said the study authors.
The researchers conducted a prospective European population-based cohort study derived from
In the study findings, the researchers found no association between alcohol consumption and risk of PD at recruitment and during lifetime. When stratified for sex, male lifetime moderate consumers (5-29.9 g/day; 5-14.9 g/day; HR, 1.58; 95% CI, 1.07-2.33; 15-29.9 g/day; HR, 1.52; 95% CI, 1.00-2.33) exhibited close to a 50% higher risk of PD compared with light consumers (0.1-4.9 g/day; HR, 1 [ref]). However, there was no exposure—response trend observed (P = .55).
Additional analyses for lifetime consumption by type of alcoholic beverage also did not show any significant association with PD risk.
“Overall, our data support previous findings from large US prospective studies that there is no association between alcohol consumption and the risk of PD,” said the study authors.
Reference
Peters S, Gallo V, Vineis P, et al. Alcohol consumption and risk of Parkinson’s disease: data from a large prospective European cohort [published online May 1, 2020]. Mov Disord. doi: 10.1002/mds.28039.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025